Novelty Nobility Partners with AGC Biologics to Advance Bispecific Drug Candidate
Novelty Nobility partners with AGC Biologics to advance a bispecific Antibody Drug Candidate (ADC) into GMP manufacturing, showcasing Japan’s bioprocessing expertise and AGC Biologics’ global development network.
Sang Gyu Park | 04/05/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy